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Current concepts of cystic fibrosis (CF) pathophysiology link ion
transport abnormalities to reduced airway surface liquid (ASL) hy-
dration and impaired mucus clearance. It is likely that correction
of the defects that cause ASL dehydration will prevent degradation
of mucus clearance, thereby preventing the initiation and/or pro-
gression of CF lung disease. A number of novel therapeutic agents
aimed at the earliest steps in disease pathogenesis are now under
development for the treatment of CF lung disease. Consequently,
there is a tremendous need to develop methods that directly assess
the effects of these agents on the underlying pathophysiologic
process in the target organ. The measurement of mucociliary clear-
ance (MCC) is a highly biologically relevant outcome, but one that
is in need of further development. Here, we describe important
methodologic aspects of MCC measurement and issues that have
limited its use as an outcome measure in the past. Furthermore,
we outline the steps that are being carried out now, and will be
carried out in the future, to improve the performance of these
studies in clinical trials. A systematic approach to optimizing and
standardizing the measurement of MCC should greatly advance
our ability to assess novel therapies at a relatively early stage of
drug development. The resulting data may then be used to select
those candidates that should be rapidly advanced into larger clinical
trials.
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The pathogenesis of cystic fibrosis (CF) lung disease is complex
and involves a progression of events that lead to chronic airway
infection and bronchiectasis. The dominant view of early disease
pathogenesis links epithelial ion transport abnormalities (see
article by Rowe and colleagues in this symposium [pp. 387–398]
[1]) to dehydration of the airway surface liquid (ASL) layer (2).
A normally hydrated ASL layer, which includes both a low-
viscosity periciliary layer (PCL) and an overlying mucus layer,
is required for optimal mucus transport in the lung (3). Mucus
dehydration dramatically alters its transportability while also
making it impervious to neutrophil influx, thus limiting their
ability to reach their bacterial targets (4). Volume depletion of
the PCL interferes with normal cilia motion and ultimately
allows contact and adhesion between the mucus layer and epithe-
lial cell surfaces. Together, these defects degrade cilia and cough-
dependent mucus clearance, which comprise the primary innate
defense mechanism for the lung (5). In CF, defective mucus
clearance is proposed to be an integral step in disease pathogene-
sis, and is the target of a number of drugs currently in the
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development pipeline. A sensitive and specific outcome measure
that directly reflects the mucus clearance defect in CF as well
as the impact of effective therapies would, therefore, be an
invaluable tool for the drug development process.
The measurement of mucociliary clearance (MCC) has, in
fact, been performed for decades via various techniques. The
inhalation of aerosolized, radiolabeled particles is the most
widely accepted technique. However, significant variation exists
in the nature of the inhaled particles, their delivery to the airway,
and the analysis and interpretation of MCC studies, and has
limited its acceptance as a reliable outcome measure. The ongo-
ing development of CF therapies aimed at normalizing ASL
hydration and mucus clearance makes refinement and validation
of the MCC measurement technique an important priority for
the CF research community. The ensuing text describes the cur-
rent status of MCC measurements and further outlines the neces-
sary refinements that will increase the utility of this outcome
measure.
TECHNICAL ASPECTS OF MCC MEASUREMENTS
The measurement of MCC or cough clearance (CC) rate requires
the delivery of an externally detectable and nonabsorbable
marker to the airways. Past studies have utilized substances
such as technetium-99m–labeled iron oxide and human serum
albumin for this purpose. More recent studies have relied on the
nebulized delivery of technetium sulfur colloid (Tc-SC) aerosols.
The unfiltered form of Tc-SC contains submicronic particles
(mean size, 0.3 m) (6) in isotonic saline. This solution is then
nebulized to form larger aerosol particles that are inhaled. After
delivery to the airways, minimal tracer penetration into the
bloodstream is observed, and the bulk of the Tc-SC mass is
thought to remain suspended within the mucus layer (7). Luminal
macrophages do, however, engulf a significant fraction of depos-
ited particles within the time frame of a typical MCC study (31%
after 100 min), but clearance of these macrophages is thought
to occur at a similar rate to free Tc-SC particles (8).
The lung deposition pattern of aerosolized particles depends
upon the characteristics of the aerosol particles (average size,
distribution of size), the breathing pattern used during inhalation
(flow rate, tidal volume), and the nature of the airways them-
selves (i.e., degree of obstruction and lung size) (9). This is
critically important, because the observed rates of MCC vary in
different lung regions, and, therefore, are highly dependent on
the deposition pattern (10). For example, MCC rates within
small airways are on the order of 1 mm/minute, whereas rates
in large airways and the trachea may be as high as 2 cm/minute
(11). Macrophage-mediated clearance of particulates deposited
in the alveoli is much slower (i.e., months). Although the ability
to manipulate aerosol characteristics and breathing patterns pro-
vides the opportunity to target and study different lung regions,
the resulting variability in lung deposition also makes the genera-
tion of reproducible MCC data difficult. Therefore, an emphasis
has been placed on devising aerosol delivery systems with a high
degree of deposition pattern reproducibility, thereby reducing
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measurement error and increasing the ability to detect differ-
ences between groups. These systems typically use an aerosol
generation device and a series of delivery adjuncts to produce
repeatable breathing patterns and consistent aerosol dosing. For
example, pneumotach devices with visual feedback are often
used to control inhalation flow rate and tidal volume within
specific ranges; metronomes can be used to guide the timing of
inhalation and exhalation; and aerosol dosimetry equipment can
be used to pulse aerosol delivery during specific portions of the
breathing cycle.
Despite careful efforts to minimize the variability of aerosol
deposition, significant differences that confound MCC data may
still occur within a patient on consecutive studies or between
groups of individuals. Therefore, it is very important that initial
deposition patterns be quantified and factored into comparisons
between studies. Deposition parameters are typically expressed
as ratios of radioactive counts in central and peripheral lung
zones made at the beginning of the clearance measurement pe-
riod (C/P ratio). In principle, peripheral zones will comprise
primarily slowly clearing small airways, whereas central regions,
although also containing the small airways, will be relatively
enriched with more rapidly clearing large airways. To define
these lung regions, either a transmission scan (using an external
radiation source) or a ventilation scan (using an inhaled radioac-
tive gas, such as xenon-133) must be performed so that the outer
lung boundaries can be identified and regions of interest assigned
(Figure 1A). Once identified, the initial aerosol deposition image
(Figure 1B) may be used to quantitate the C/P ratio. Clearance
rates in each region (i.e., whole lung, central, peripheral) may
then be expressed as a function of retained counts versus time.
When a xenon-133 ventilation scan is used to define lung bound-
aries, the C/P ratio can be further normalized to the lung volume
contained within each lung zone using the counts measured after
achieving equilibrium during xenon inhalation (12). Alterna-
tively, deposition may be described using a parameter called the
Figure 1. (A ) A xenon-133
equilibrium scan is used to iden-
tify lung (L, left; R, right) bound-
aries in a normal subject. Using
this outline, central (C) and pe-
ripheral (P) regions of interest
are assigned. (B ) This deposi-
tion image was obtained imme-
diately after the inhalation of
technetium sulfur colloid in the
same subject. (C ) Mean rates of
clearance from 12 subjects with
cystic fibrosis are shown at
baseline (open squares) and im-
mediately after inhalation of hy-
pertonic saline (HS) (16). The
“fast phase” (through ~ 20 min;
blue dashed line), reflecting
clearance from large airways,
and “slow phase” (from 40 min
to start of cough clearance mea-
surement; red dashed line), re-
flecting smaller airway clear-
ance, are highlighted on the
post-HS clearance curve. (D )
The effect of the ratio of radio-
active counts measured in the
central and peripheral lung zones (C/P ratio) on rates of mucociliary clearance, as denoted by particle retention through 120 minutes, in a cohort
of normal study subjects. Images in (A ) and (B ), and data in (D ) (previously unpublished) courtesy of W.D. Bennett.
“penetration index” (PI). The PI is the ratio of radioactive counts
per pixel area in the peripheral lung zone to counts per pixel
area in the central zone (13). Because increased deposition in
central airways, as indexed by a high C/P ratio or low PI, is
associated with increased rates of MCC, it is critical to account
for this potential confounder in the analysis of these data (Figure
1D) (14). A different approach to circumventing errors that
result from differences in aerosol deposition focuses on clearance
measured in the peripheral lung zone (12). Because this region
contains a somewhat more homogeneous composition of airways
than the central or whole-lung regions, resulting clearance rates
are expected to be less sensitive to the initial deposition pattern.
This approach can be problematic, however, because reduced
tracer deposition (with traditional delivery systems) and intrinsi-
cally slower clearance rates in this region lead to a smaller sig-
nal:noise ratio. Drug effects on central/larger airways may also
be missed by this approach.
The temporal relationships between a particular intervention,
the delivery of inhaled radiolabel, and the onset of imaging are
also important considerations. This is particularly true because
of the two-phase nature of clearance that is typically observed
(Figure 1C) (7). A fast clearance phase is usually noted immedi-
ately after the administration of the Tc-SC aerosol, lasting for
a period of 15–40 minutes. A slower clearance phase is then
observed, which lasts through the rest of most typical imaging
periods (i.e., 1–2 h). It is thought that the fast phase of clearance
represents the initial, rapid transit of deposited particles from
larger airways, whereas the slow phase reflects small airway
clearance. It is possible, however, that slower clearance phases
could reflect the movement of the radiolabel into a less clearable
compartment (e.g., due to mixing into the PCL vs. residence in
the mucus layer, or intracellular uptake vs. free Tc-SC label),
rather than being a function of airway deposition. The time
between aerosol administration and the commencement of im-
aging will affect the proportion of the fast phase that is sampled,
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and could potentially have substantial effects on the overall
measured rate. Comparative trials, therefore, must carefully
match the time between Tc-SC delivery and the start of imaging.
Once subjects have inhaled the radiolabeled particles, they
are positioned in front of a camera that detects and records
emitted  radiation. The sensitivity and spatial resolution of the
resulting image will be a function of the inhaled Tc-SC dose,
the camera resolution (i.e., pixel matrix size), and the thickness
of the associated collimator. Collimators are thin plates that are
placed between the patient and the detecting surface of the 
camera, which filter out “scatter,” allowing only radiation coming
from a direction perpendicular to the camera to reach the im-
aging surface (15). In general, camera properties that improve
resolution (more pixels/inch, thicker collimator) also reduce its
sensitivity, causing a trade-off that can only be compensated by
increasing the administered Tc activity. Longer acquisition times
for each  camera image will also improve the signal available
for analysis while reducing the number of images (i.e., data
points) that can be collected during the clearance measurement.
Patient positioning during imaging is another factor that varies
between centers, with some studies using seated positioning (16)
and others using recumbent positioning (13). Seated positioning
provides for easier aerosol delivery and, arguably, a more physio-
logically realistic assessment. Recumbent positioning may im-
prove subject comfort and minimize movement during imaging.
Differences in rates of clearance as a result of patient position
have not been explored. Finally, images used in the calculation
of MCC must be corrected for decay of the isotope and for
background radiation level. Typically, only the right lung is ana-
lyzed, because activity in the stomach can bias left-lung counts.
MCC measurements are often supplemented by measure-
ments of CC, and by extended (i.e., 24-h) measurements of
clearance. CC is typically measured by having the subjects cough
at prescribed frequencies through an expiratory flow measure-
ment device to gauge the forcefulness of each cough. In most
cases, a period of CC is included some time after the initial
measurement of MCC (16, 17), although, in this configuration,
the amount of isotope available in airways available to clearance
by cough (i.e., more central airways) may be significantly re-
duced, thereby lowering the sensitivity of this measurement.
Furthermore, because a preceding period of cilia-based clear-
ance will have variably reduced the amount of isotope accessible
to clearance by cough on different study days, a further normal-
ization (e.g., C/P measured at start of coughs) must be used
before comparing CC measurements. Current protocols for CC
measurement in CF, therefore, are suboptimal, because study
designs used to measure this clearance parameter have priori-
tized it below cilia-dependent clearance measurements.
Measurements of 24-hour clearance have gained renewed
interest recently, and serve several purposes. First, they provide
an additional means of assessing aerosol deposition pattern, be-
cause aerosol initially delivered to the alveoli will be retained
for a much longer period than aerosol delivered to the airways
(10, 18). Second, these measurements can also be used to provide
a measurement of cumulative clearance over longer time do-
mains, which, in turn, may illustrate therapeutic efficacy (16).
The relative contribution of (1) alveolar deposition, (2) slow-
phase clearance from peripheral airways, and (3) mixing into a
poorly cleared compartment of the ASL to 24-hour measures
of clearance remains unclear. In addition, because the half-life
of technetium-99m is approximately 6 hours, assessment of 24-
hour clearance requires the delivery of sufficient initial tracer
activity to ensure signal levels that are sufficiently above back-
ground at later timepoints.
MCC AS AN OUTCOME MEASURE IN CF
Comparison of MCC measurements in healthy subjects and pa-
tients with CF, as well as other accumulated experiences with
MCC measurements in clinical trials, provides an opportunity
to judge the ability of MCC measurement techniques to serve
as a biomarker of disease and/or drug activity. In this section,
we will review both positive and negative data pertinent to these
issues, and will discuss important issues that should be addressed
in future studies.
Several published comparisons of MCC measurements in un-
affected individuals and subjects with CF are available for re-
view. In the largest, by Robinson and colleagues, a retrospective
review of one laboratory’s experience in normal subjects (n 
17 subjects/22 studies) and subjects with CF (n  59 subjects/
184 studies) was reported (13). Salient features from this study
include the fact that mucus clearance was indeed markedly im-
paired in subjects with CF in comparison to the normal cohort.
This reduction in clearance in patients with CF was most appar-
ent in central and intermediate regions (vs. peripheral) and in
apical and “mid” zones (vs. basal). In each of the most affected
regions, clearance was approximately 50% that of the normal
rate. Interestingly, the observed reductions in clearance ap-
peared to be independent of baseline lung function, and even a
subgroup of subjects with CF with normal FEV1 measurements
(n  17) manifested markedly abnormal clearance rates. In other
comparisons of clearance rates between unaffected individuals
(n  12–17 each) and patients with CF with mild to moderate
impairment in lung function (n  12–20 each), whole-lung clear-
ance was, in fact, not different (12, 16). However, MCC indices
that reflect clearance from small airways, particularly peripheral
zone clearance and 24-hour clearance, were significantly reduced
(12, 16, 19). Finally, a study of long-term clearance from CF
airways used a delivery technique that specifically targeted small
airways with a radiolabeled particle that allowed detection of
clearance over a 3-week period. This study demonstrated signifi-
cantly increased particle retention after 24-hours in subjects with
CF (67 vs. 48%, CF vs. normal, respectively). Particle retention
between 7 and 21 days was not affected. Although the authors
contended that these data did not reflect a small airway clearance
defect in CF, but, rather, reflected delayed clearance from large
and medium-sized airways, this interpretation is debatable. In
fact, because there was very little predicted large/medium-sized
airway deposition with the inhalation technique used (20–25%
of total deposited fraction), it would appear likely that delayed
small airway clearance did indeed contribute to the difference
in 24-hour retentions between normal subjects and those with
CF. The lack of a difference between clearance after 7 days may
signify that clearance mechanisms other than MCC (e.g., cellular
uptake) are dominant over these longer time domains (20). The
sum of these data, therefore, support the hypothesis that a mucus
clearance defect exists in CF, even in the setting of mild airway
obstruction, but that this defect may be inhomogeneous and
primarily localized to the small airway compartment at this stage
of disease.
MCC measurements have now been used in a number of
small clinical trials (Table 1). An acute stimulation of MCC was
noted with several therapeutics that are now being developed
for CF lung disease. These include hypertonic saline (HS) (16,
21), mannitol (17), amiloride (22), and uridine 5-triphosphate
(UTP) (12). HS and mannitol, both osmotic agents, appeared
to yield the largest acute stimulation of clearance, whereas UTP
only accelerated peripheral lung clearance rates in patients with
CF when combined with amiloride. MCC was also measured
during repetitive dosing of HS in patients with CF, and demon-
strated sustained improvements in clearance rates (i.e.,  8 h
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TABLE 1. MCC MEASUREMENTS IN CLINICAL TRIALS
Proposed Mechanism
Drug of Action Outcome Investigator/Reference Comments
Amiloride (1 mM, Block sodium channels; Acutely increased MCC; App and colleagues (22) Nonsignificant effect of amiloride reported
nebulized twice daily) increase ASL volume sustained improvement by Bennett and colleagues in smaller
vs. saline; n  23 (n  6 after 3 wk cohort (12)
treated  3 wk)
UTP (n  14) P2Y2 agonist; stimulates Increased peripheral lung Bennett and colleagues (12) Peripheral clearance measured to avoid
chloride secretion and clearance in CF when confounding effects of higher C/P ratio
cilia beat frequency combined with and increased cough in CF.
amiloride.
Hypertonic saline (7% Increase ASL volume via Acute and sustained effects Robinson and colleagues 0.9–12.0% NaCl studied by Robinson and
NaCl; n  10–24) osmotic properties on MCC (21); Donaldson and colleagues (21); 12% saline was not
colleagues (16) well tolerated
Mannitol (300 mg dry Increase ASL volume via Acutely increased MCC Robinson and colleagues (17) Mannitol compared to 6% NaCl; yielded
powder inhaler; n  12) osmotic properties similar changes in MCC and CC
Sodium 4-phenylbutyric Reduce F508 No change in MCC or CC Laube and Zeitlin Timing of MCC measurement may have
acid (20 g/d by mouth degradation; stimulate from baseline after 7 d (unpublished data) been inappropriate to detect any acute
 7 d; n  5) chloride transport of treatment effect of drug (i.e., 	 7 d).
Terbutaline (by inhalation; Increase ciliary beat No acute effect on MCC Mortenson and colleagues Absent cAMP-mediated chloride secretion
n  10) frequency in CF in CF (14, 26) in CF may limit effect; sample size
inadequate to detect subpopulation of
responders
Sodium bicarbonate (1.5% Correct low pH ASL in CF, No acute effect on MCC Corcoran and colleagues (27) Delivered dose may have been too low;
solution  5 ml by which may increase cilia sample size inadequate to detect
inhalation; n  10) beat frequency (34) subpopulation of responders
Pulmozyme (2.5 mg twice Reduce mucus viscosity No difference in MCC vs. Laube and colleagues (28) Effect on CC is unknown since it was not
daily by inhalation  6 d; placebo after 6 d of assessed
n  10 per treatment treatment
group)
Moli1901 (2.5 mg  1 dose Stimulate chloride No change from baseline at Laube and Zeitlin Delivered dose may have been too low.
by inhalation; n  3) transport (12) 24 h after dosing (unpublished data) Timing of MCC measurement may
have been inappropriate to detect any
acute effect of drug (i.e., 	 24 h).
Definition of abbreviations: ASL  airway surface liquid; CC  cough clearance; CF  cystic fibrosis; C/P  radioactive counts in central and peripheral lung zones;
MCC  mucociliary clearance; UTP  uridine 5-triphosphate.
after prior dose) within 2 weeks of initiating this therapy. In
addition, an acute stimulation of clearance could still be observed
at the end of the 2-week dosing period (i.e., no tachyphylaxis).
Interestingly, the combination of amiloride and HS yielded
acute, but not sustained, improvements in MCC, and did not
improve lung function or symptoms, unlike HS alone, which did
yield improvements in these clinical outcomes (16). Given that
HS not only improved lung function, but also has been shown
to reduce the frequency of pulmonary exacerbations (23), it is
enticing to speculate that its sustained effect on MCC might in
fact serve as a surrogate marker for improvement in one of
these more traditional clinical outcomes. Clearly, though, this
association will require additional study in order to validate a
true causal link. Longer-acting and more potent analogs of UTP
(denufosol tetrasodium; Inspire Pharmaceuticals, Inc., Durham,
NC) and amiloride (PS 552-02; Parion Sciences, Inc., Durham,
NC) are currently in development for CF, with the hope that
these agents will also yield sustained improvements in MCC. Of
note, PS 552–02 has been reported to improve MCC in normal
subjects, and to have some evidence of pharmacodynamic dura-
bility (effect detectable at 4 h after dosing) (24), whereas the
effects of denufosol on MCC in humans are not yet known.
In contrast to these agents that have been shown to accelerate
MCC rates, a variety of other therapeutics that were predicted
to improve MCC in CF have failed to show measurable effects.
Although these failures may truly reflect a lack of efficacy of
the study agent, it must also be considered that improved MCC
measurement techniques and/or study designs might have uncov-
ered beneficial effects. Therefore, it is instructive to examine
these studies as well. Drugs proposed to reduce the degradation
of the CF transmembrane conductance regulator protein (i.e.,
sodium 4-phenylbutyric acid [25]), increase ciliary beat fre-
quency (i.e., terbutaline [26] and sodium bicarbonate [27]), de-
crease the viscosity of the mucus (Pulmozyme [28]; Genentech,
Inc., South San Francisco, CA), or increase the ASL volume by
stimulating chloride transport (Moli1901; Lantibio, Inc., Chapel
Hill, NC) have been tested in patients with CF at different
centers. Table 1 provides an outline of these studies, with poten-
tially relevant shortcomings that prevented a positive outcome.
There are a number of possible explanations related to study
design for the negative outcomes reported in these studies. First,
the effect of a given drug may be short lived, and an effect on
MCC may only be detected if the timing between dosing and
MCC measurement is appropriate. If the pharmacodynamic
properties of a drug are unknown, MCC assessments at acute
and delayed time points after dosing may be required. Of note,
the acute effects of sodium 4-phenylbutyric acid and Moli1901
on MCC were not assayed by nature of their respective study
designs, and could account for the absence of any detectable
effect on MCC. Second, as with any drug, an effective dose must
be reached. This issue may be particularly problematic with
inhaled therapies if formal drug delivery and pharmacokinetic
information is not available before choosing a dose in “proof of
mechanism” or therapeutic trials. Certainly the CF lung can be
a particularly challenging target organ due to inhomogeneous
ventilation/delivery and physical barriers posed to some drugs
by a thickened mucus layer. Third, the MCC parameter being
assessed should match the effect of the drug being delivered.
For example, Pulmozyme may, in fact, alter sputum rheology in
a fashion that predicts improved CC, but not cilia-dependent
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clearance (29). Therefore, to capture the effect of this drug on
mucus clearance, a dedicated CC study might be necessary rather
than the typical MCC study format, where cough is either not
measured, or is measured after 60–90 minutes of measuring cilia-
dependent clearance. Similar problems could also be encoun-
tered if an agent primarily affects clearance from small versus
large airways and the MCC study (i.e., the radiolabeled aerosol
delivery strategy) is not designed to assess this airway region.
Finally, a large number of patient- and study-related factors
might increase the variability of MCC measurements or other-
wise reduce the ability to detect meaningful differences affected
by a novel therapy. For example, one must consider the other
therapies being used by a patient, including those that might
affect the baseline rate of MCC or CC (e.g., HS or rhDNase,
antibiotic therapies), or alter the deposition of the study drug
and/or radiotracer (e.g., bronchodilators). Holding potentially
confounding medications or treatments (i.e., mechanical airway
clearance maneuvers), or at least standardizing their timing be-
fore MCC measurement, must be considered carefully. Un-
wanted variability may also be encountered in longer trials, given
the intrinsic variability of CF lung disease, thereby reducing
study power and increasing necessary sample size to detect clear-
ance rate changes in both crossover and parallel-group designs.
Given these inherent problems, study designs that carefully con-
sider these factors, and analysis plans that account for common
confounders, are essential.
FUTURE DIRECTIONS
Despite the importance of being able to accurately quantitate
MCC/CC as an outcome for CF therapeutic trials, only a few
CF centers have developed the capacity to perform these studies.
Unfortunately, the techniques used to measure MCC/CC at these
centers are not standardized, making comparison of results diffi-
cult at times. Furthermore, with the limited use of MCC measures
as an assessment of clinical efficacy, no rigorous assessments of
intrasubject variability for any of the currently used methodolo-
gies have been made. Because an increasing number of drugs
designed to improve MCC/CC in CF are entering the therapeutic
pipeline, it is vital to develop standard techniques for these
measures in order to efficiently screen compounds at an early
stage of development and rapidly advance those with the highest
chance of being effective.
Perhaps the most important element to standardize of MCC/
CC studies is the delivery of the radiolabeled aerosol. Because
clearance rates are highly dependent on regional deposition of
the radiolabeled particles in the lung, aerosol delivery to the
bronchial airways must occur in a reproducible manner to mini-
mize intra- and intersubject variability in particle deposition.
However, it is primarily these delivery methods that differ be-
tween various study sites. In an effort to address this problem,
aerosol delivery techniques that have been shown to improve
the reproducibility of deposition are currently being optimized
and simplified in a multicenter effort supported by the CF Foun-
dation. These studies are also aimed at the standardization of
data acquisition and image analysis protocols for assessing initial,
regional deposition patterns, and the subsequent retention-versus-
time MCC data. Finally, because serial studies will be performed,
data pertinent to within-subject repeatability and between-
center reproducibility will be generated. This collaborative effort
should significantly advance efforts to make MCC measurements
comparable at CF centers that are currently active in this field.
The current methods for measuring MCC are designed to
target delivery of radiolabeled particles to the bronchial airways,
but the observation times and inhalation maneuvers are such
that the measured MCC rates are primarily reflective of the
largest of these airways. On the other hand, because the initial
pulmonary pathophysiology in CF occurs in the small, peripheral
conducting airways (30), it is likely that mucociliary dysfunction
also begins there, as evidenced by two previously described com-
parisons of MCC in normal subjects and those with CF (12, 16).
An inhalation method that has been employed to specifically
target particle deposition to the small, bronchial airways is the
extremely slow inhalation technique described by Anderson and
colleagues (31). These investigators had subjects inhale large
particles, 6-m mass median aerodynamic diameter, with very
low inhalation flow rates (0.04 L/s), conditions under which they
predicted that these large particles would settle out in the small
bronchial airways before reaching the alveolar region. The subse-
quent clearance kinetics that they measured through 96 hours
after deposition supported this contention (i.e., a slow but sig-
nificant clearance of particles from 24 to 96 hours, consistent
with particle clearance from small airways. Incorporating such
an inhalation method, along with retention measurements at
later time points (6–24 h), into future studies may provide a
better index of small airway clearance in CF for analysis of
therapeutic effects in these airways. This may be particularly
important for agents not expected to yield large, rapid ASL
volume fluxes in central airways, and for drugs that preferentially
affect small airways in CF, as was seen with the combination of
UTP and amiloride (12).
Although uncontrolled, spontaneous coughing can confound
measures of MCC (32), more standardized, controlled measures
of CC can be obtained by incorporating fixed numbers of volun-
tary coughs during the image acquisition period for assessing
particle clearance (32, 33). Because certain agents may change
sputum rheology in a manner that preferentially improves this
mucus clearance parameter (vs. cilia-dependent clearance),
MCC/CC protocols that adequately measure CC are important.
Of note, MCC/CC studies that are primarily focused on the
measurement of CC have not been performed in CF, and pre-
viously used protocols have serious shortcomings in the assess-
ment of this variable. The development of improved methodolo-
gies that incorporate standardized coughs at a time point closer
to the delivery of radiolabel should be considered. Finally, spon-
taneous cough frequency, as a potential covariate in the analysis
of MCC/CC, should also be recorded throughout the imaging
period in all MCC/CC studies.
Other aspects of MCC study designs should also be consid-
ered in relation to the study drug’s proposed action. For example,
if a drug is thought to have an immediate effect on MCC/CC,
does not alter airway mechanics, but does elicit spontaneous
coughing during administration, the study drug dosing should
occur immediately before the inhalation of radioaerosol and
subsequent  camera monitoring. On the other hand, if a drug
acts acutely, but does alter airway mechanics (e.g., a bronchodila-
tor) and doesn’t elicit spontaneous cough, then dosing should
occur immediately after inhalation of the radioaerosol to avoid
differences in deposition pattern on drug and placebo study days.
Finally, if a drug has a delayed onset while not affecting airway
mechanics, then inhalation of radioaerosol should occur some
time after inhalation of the drug (depending on peak effect or
durability of the drug). As part of the preclinical trial develop-
ment of new therapies to improve MCC/CC in CF, we recom-
mend an acute, double-blinded, cross-over study design to first
show biological effect. A positive outcome in such a trial may
be followed by a longer design (e.g., 2 wk of repetitive dosing),
similar to that recently performed for aerosolized HS (16). Such
a trial allows detection of MCC/CC changes (e.g., sustained
effects on MCC rate) that might only occur with longer treatment
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periods, as well as comparison with other lung function
endpoints.
CONCLUSIONS
The measurement of MCC and CC is a very promising, but
incompletely developed, biomarker for CF clinical research.
There is strong evidence that measurements of MCC/CC are
biologically and clinically relevant, in that they have been shown
to reflect the underlying disease process and to be responsive to
therapies aimed at normalizing ASL volume (e.g., HS, mannitol,
amiloride, UTP). In addition, this outcome measure has the
distinct advantage of being an index of both disease activity and
drug effect in the critical target organ, the lung, as opposed to
other outcome measures that might be used in drug trials of ion
channel–directed therapies (e.g., nasal potential difference or
sweat chloride). As a result, a positive effect on MCC testing
might be more likely to translate into clinical benefit than a
nonpulmonary outcome. Shortcomings that are currently being
addressed include the lack of procedural standardization be-
tween centers that can perform MCC. This has limited the ability
to compare results of studies performed at different centers, and,
more importantly, has limited our ability to perform multicenter
studies of new CF therapies using MCC as an outcome.
Once a standard operating procedure is refined and agreed
upon, it will be important to assess the repeatability and repro-
ducibility of these studies to facilitate the appropriate design of
clinical trials. It is possible, however, that a single MCC/CC
protocol may not be adequate to address all aspects of mucus
clearance, or be optimally suited for testing of all drugs in the
development pipeline. Alternatively, several protocols could be
created to assess different aspects of mucus transport (e.g., CC,
small airway clearance), although each would need to be formally
validated. Whether or not any particular aspect of an MCC
assessment (e.g., a sustained effect on whole-lung clearance) will
be shown to actually predict a clinically relevant outcome (e.g.,
reduced exacerbation frequency)—in other words, serve as a
surrogate marker—is unclear, but would be an exciting develop-
ment. Ultimately, dissemination of the ability to perform MCC
measurements to other research centers should be feasible, and
would greatly enhance the ability to test candidate CF therapies
in a much more rapid and thorough fashion.
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